Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 24 of 98 for:    grams | maltodextrin

A Double Blind Study on the Gastrointestinal Effects of Arabinoxylan (Leaf Fiber Extract).

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04100460
Recruitment Status : Not yet recruiting
First Posted : September 24, 2019
Last Update Posted : September 24, 2019
Sponsor:
Collaborator:
Biofortis, Merieux NutriSciences
Information provided by (Responsible Party):
Comet Bio Inc.

Brief Summary:
The objective of this study is to investigate the effect on Arabinoxylan on gastrointestinal (GI) tolerance, bowel habits, and microbiota in adults. The study is a randomized, placebo-controlled, crossover, single-center trial with 3 study periods separated by minimum 2-week washout periods. 45 healthy adults will be recruited for the trial. Participants will be required to drink a beverage twice a day for 3 weeks during each study period. The beverage will contain either approximately 7.25 grams of Arabinoxylan leaf fiber extract per day, or approximately 14.5 grams of Arabinoxylan leaf fiber extract per day, or will not contain any Arabinoxylan (control). Subjects will record their bowel movements daily, fill out daily questionnaires about their gastrointestinal systems, and record their food intake at specified times during the study. Stool samples will also be collected prior to and at the end of each study period for analysis of bacteria composition.

Condition or disease Intervention/treatment Phase
Gastrointestinal Tolerance Dietary Supplement: 7.25 grams of Arabinoxylan leaf fiber extract Dietary Supplement: 14.5 grams of Arabinoxylan leaf fiber extract Dietary Supplement: Control - No Arabinoxylan Not Applicable

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 45 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description: The study is a randomized, placebo-controlled, crossover, singe-center trial with one screening visit and 3 test periods separated by minimum 2 - week washout periods.
Masking: Double (Participant, Investigator)
Masking Description: Study personnel will remain blinded to the sequence assigned to subjects throughout the study. A set of sealed unblinding envelopes will be provided to the Clinical Investigator for use in an emergency situation where a subject's health is at risk.
Primary Purpose: Other
Official Title: A Randomized, Placebo-controlled, Crossover Study to Investigate the Effect of Arabinoxylan on Gastrointestinal Tolerance and Microbial Changes in Generally Healthy Adults.
Estimated Study Start Date : September 2019
Estimated Primary Completion Date : March 2020
Estimated Study Completion Date : May 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: 7.25 grams of Arabinoxylan leaf fiber extract
Participants are given 7.25 grams of Arabinoxylan daily
Dietary Supplement: 7.25 grams of Arabinoxylan leaf fiber extract
Participants are given 7.25 grams of Arabinoxylan daily

Experimental: 14.5 grams of Arabinoxylan leaf fiber extract
Participants are given 14.5 grams of Arabinoxylan daily
Dietary Supplement: 14.5 grams of Arabinoxylan leaf fiber extract
Participants are given 14.5 grams of Arabinoxylan daily

Placebo Comparator: Control - No Arabinoxylan (Maltodextrin)
Participants are given no Arabinoxylan
Dietary Supplement: Control - No Arabinoxylan
Participants are given no Arabinoxylan




Primary Outcome Measures :
  1. GI Symptoms Score [ Time Frame: 3 weeks +/- 3 days ]
    Composite GI symptoms Scores obtained from the Daily GI Tolerance Questionnaire will be obtained by summing the ratings to the 8 individual scores (see below in Outcome 2).

  2. Individual GI symptoms ratings [ Time Frame: 3 weeks +/- 3 days ]
    Ratings for each of the 8 individual GI symptoms Scores [gas/flatulence, nausea, vomiting, abdominal cramping, abdominal distention/bloating, borborygmus/stomach rumbling, burping, and/or reflux (heartburn)] will be ranked on a 4-point scale (none, mild, moderate, severe) for symptoms experienced over the previous 24 hours.


Secondary Outcome Measures :
  1. Bowel Habits Dairy [ Time Frame: 3 weeks +/- 3 days ]
    Compilation of bowel habits obtained by each subject's Bowel Habits Diary

  2. Fecal Microbiome [ Time Frame: 3 weeks +/- 3 days ]
    Results of the stool samples that will examine diversity, composition, and changes in bacteria.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • BMI of 18.5 to 35.0 kg/m2 at Visit 1
  • Non- smokers/former users (cessation less than or equal to 12 months)
  • Regular bowel movements; not constipated
  • Willing to maintain physical activity patterns, body weight, and habitual diet throughout the trial
  • Willing to limit alcohol consumption to less than or equal to 2 drinks per day
  • Willing to avoid vigorous physical activity for 24 hrs prior to and during visits
  • Willing to refrain for exclusionary medications, supplements, and products throughout study.
  • Willing to comply with the visit schedule and fecal sample collection/processing/storage requirements
  • No health conditions that would prevent him/her from fulfilling the study requirements based on medical history and routine laboratory test results.
  • Understands the study procedures and signs forms providing consent and authorization of release of relevant protected health information to investigator

Exclusion Criteria:

  • Abnormal laboratory test results of clinical significance at Visit 1
  • Clinically important GI condition that would potentially interfere with the evaluation of the study product
  • Recent (within 2 weeks of Visit 1) history of an episode of acute GI illness
  • Self reported history (within 6 weeks of visit 1) of constipation
  • Uncontrolled and/or clinically important pulmonary, cardiac, hepatic, renal, endocrine, hematologic, immunologic, neurologic, psychiatric or biliary disorders
  • Uncontrolled hypertension
  • Known allergy, intolerances or sensitivity to any of the ingredients in the study product
  • Extreme dietary habits
  • History or presence of cancer in the prior 2 years, except for non-melanoma skin cancer
  • Major trauma or any other surgical event within 3 months of Visit 1
  • Signs or symptoms of an active infection of clinical relevance within 5 days of Visit 1
  • Weight loss or gain of greater than 4.5 kg in the 3 months prior to Visit 1
  • Currently or planning to be on a weight loss regimen during the duration of the study
  • Antibiotic use within 3 months of Visit 1
  • Use of steroids within 1 month of Visit 1
  • Chronic use of anti-inflammatory medications within 1 month of Visit 1
  • Use of medications and or dietary supplements known to influence GI function
  • Consumption of fermented foods or beverages that do or might contain live probiotics within 2 weeks of Visit 1
  • Participated in endoscopy or endoscopy prep within 3 months of Visit 1
  • Female that is pregnant, planning to be pregnant during the study period, lactating, or is unwilling to use a medically approved form of birth control during the study period
  • Recent history (within 12 months of screening) of substance abuse
  • Has a condition the Investigator believes will interfere with the subjects inability to provide informed consent, confound the interpretation of the results, or put the subject at risk

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04100460


Contacts
Layout table for location contacts
Contact: Kristen Sanoshy 630-330-0463 kristen.sanoshy@mxns.com
Contact: Christy Cangelosi 847-721-6207 ccangelosi@comet-bio.com

Sponsors and Collaborators
Comet Bio Inc.
Biofortis, Merieux NutriSciences
Investigators
Layout table for investigator information
Principal Investigator: Kathleen Kelley, MD Biofortis, Merieux NutriSciences
Study Director: Rich Troyer Comet Bio Inc.

Additional Information:
Publications:
Layout table for additonal information
Responsible Party: Comet Bio Inc.
ClinicalTrials.gov Identifier: NCT04100460     History of Changes
Other Study ID Numbers: BIO-1907
First Posted: September 24, 2019    Key Record Dates
Last Update Posted: September 24, 2019
Last Verified: September 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Comet Bio Inc.:
Fecal Microbiota
Gastrointestinal tolerance
Bowel habits